RecruitingPhase 1NCT05040217

A Clinical Trial of AAV2-BDNF Gene Therapy in Early Alzheimer's Disease and Mild Cognitive Impairment

Studying NON RARE IN EUROPE: Alzheimer disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Mark Tuszynski
Principal Investigator
Mark Tuszynski, M.D., Ph.D.
University of California, San Diego
Intervention
AAV2-BDNF Gene Therapy(genetic)
Enrollment
12 enrolled
Eligibility
50-80 years · All sexes
Timeline
20222027

Study locations (2)

Collaborators

Ohio State University

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05040217 on ClinicalTrials.gov

Other trials for NON RARE IN EUROPE: Alzheimer disease

Additional recruiting or active studies for the same condition.

See all trials for NON RARE IN EUROPE: Alzheimer disease

← Back to all trials